USA FDA House - Search News

FDA, NIH and Trump

Trump’s picks to run FDA and NIH win approval from Senate’s health committee

Jay Bhattacharya, nominee for National Institutes of Health director, and FDA pick Marty Makary clear key Senate committee.

Bloomberg on MSN · 13h

Senate Committee Votes to Advance Trump’s FDA, NIH Nominees

A key US Senate panel voted to advance the nominations of President Donald Trump’s picks to lead the Food and Drug Administration and the National Institutes of Health. The nominees will next face confirmation votes before the full Senate.

New York Post on MSN · 12h

Trump’s FDA and NIH picks clear committee, teeing up final Senate confirmation

President Trump’s nominees to head the National Institutes of Health (NIH) and Food and Drug Administration (FDA) cleared a key Senate committee largely along party lines Thursday, paving the way for a full floor vote to confirm them.

FDA, Two Days and lawyer resigns

Bloomberg on MSN · 10h

Top FDA Lawyer Resigns Two Days After Appointment Announced

The US Food and Drug Administration’s top lawyer resigned on Thursday, two days after her appointment was announced, the agency posted on the social media site X.

The Hill on MSN · 8h

FDA top lawyer resigns days after starting job

The U.S. Food and Drug Administration’s chief counsel resigned two days after her appointment, according to a Thursday announcement from the agency. “Hilary K. Perkins has resigned from her

U.S. News & World Report · 12h

US FDA's Top Lawyer Hilary Perkins Resigns Two Days Into Role

Makary, who is yet to be confirmed to the FDA's top role, has said he would take a "solid, hard look" at the data the FDA collects through its risk mitigation program on mifeprist

2don MSN

House passes bill to fund federal agencies through September, though prospects unclear in Senate

The House has passed legislation to avert a partial government shutdown and fund federal agencies through September.

1don MSN

RFK Jr. wants to eliminate FDA’s controversial food additive program. Here’s why that matters

It’s time to revamp the FDA’s “generally recognized as safe,” or GRAS, program that allows companies to add untested ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results